Although, the TARGET pediatric AML study did not report PML–RARA+ APL patients, who are often considered separately for therapeutic reasons, they make up to of 5–10% of pediatric AML patients in the United States (105). This evidence concerns the gene RARA and acute promyelocytic leukemia.